Beata Korytowsky
Pfizer (United States) · 138 works · 1,718 citations · h-index 20
Top works
- Survival of U.S. Medicare patients with advanced non-small cell lung cancer by line of therapy.
- Randomized Phase II Trial of Sunitinib on an Intermittent Versus Continuous Dosing Schedule As First-Line Therapy for Advanced Renal Cell Carcinoma
- Methods for Adjusting for Bias Due to Crossover in Oncology Trials
- Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non–Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153)
- Sunitinib objective response in metastatic renal cell carcinoma: Analysis of 1059 patients treated on clinical trials
- Fluorouracil, Leucovorin, and Irinotecan Plus Either Sunitinib or Placebo in Metastatic Colorectal Cancer: A Randomized, Phase III Trial
- Patient-reported outcomes (PROs) in patients (pts) with pancreatic neuroendocrine tumors (NET) receiving sunitinib (SU) in a phase III trial.
- P3.02c-026 Is Nivolumab Safe and Effective in Elderly and PS2 Patients with Non-Small Cell Lung Cancer (NSCLC)? Results of CheckMate 153
- Tumor mutational burden in lung cancer: a systematic literature review
- Pre- and postmenopausal high-risk women undergoing screening for ovarian cancer: anxiety, risk perceptions, and quality of life
- Estimating 1- and 5-year relative survival trends in colorectal cancer (CRC) in the United States: 2004 to 2014.
- Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial
- Real-World Outcomes in Metastatic Renal Cell Carcinoma: Insights From a Joint Community-Academic Registry
- Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial
- “Real World” Treatment of Metastatic Renal Cell Carcinoma in a Joint Community-Academic Cohort: Progression-Free Survival Over Three Lines of Therapy
- Real-World Clinical Impact of Immune Checkpoint Inhibitors in Patients With Advanced/Metastatic Non–Small Cell Lung Cancer After Platinum Chemotherapy
- Real-world Treatment Patterns and Clinical Outcomes Across Lines of Therapy in Patients With Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer
- Cost-effectiveness analysis of nivolumab for the treatment of squamous cell carcinoma of the head and neck in the United States
- Sunitinib objective response (OR) in metastatic renal cell carcinoma (mRCC): Analysis of 1,059 patients treated on clinical trials.
- Characterizing fatigue associated with sunitinib and its impact on health‐related quality of life in patients with metastatic renal cell carcinoma